Crohn's Disease and Colitis Trial, Recruiting NCT06398626 Sponsor: Pfizer Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06398626
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are aged 18 years or older but under 65 years old at the start of the study
  • People who have been diagnosed with ulcerative colitis (UC) that is moderately to severely active, and whose doctor has prescribed them a medicine called etrasimod for this condition
  • People who have read and signed a consent form, showing they have been told about all important aspects of the study (a legal representative may sign on their behalf if needed)

Who may not be able to join:

  • People whose symptoms or test results suggest they may have Crohn's disease rather than ulcerative colitis
  • People whose doctor believes they are likely to need hospitalisation for a medical or surgical procedure related to their UC (such as bowel surgery) within the next 12 weeks
  • People who currently show signs of a very serious UC flare-up, including conditions known as acute severe UC, fulminant colitis, or toxic megacolon (confirm with trial site)
  • People who have already had a stoma (a surgically created opening in the abdomen) or who have a planned UC surgery that would require a hospital stay
  • People who have previously taken etrasimod, or who have taken part in any clinical study involving etrasimod
  • People who are currently also taking certain other medicines alongside etrasimod, including methotrexate, azathioprine, mercaptopurine, or tioguanine
  • People who are currently also taking certain other advanced UC treatments, including biologic medicines (such as TNF blockers, integrin blockers, or cytokine blockers), specific medicines called JAK inhibitors (filgotinib, tofacitinib, or upadacitinib), or any other medicine in the same class as etrasimod (S1P receptor modulators)
  • People who are unwilling or unable to download and use a web-based tool on a personal device to complete regular health questionnaires
  • Staff members at the research site or Pfizer employees who are directly involved in running the study, staff supervised by the study investigator, and their immediate family members

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
17 September 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of patients with symptomatic remission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov